You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
花旗:料中資醫藥股上季業績強勁 看好中生製藥等
格隆匯 10-18 13:46

花旗發表報告表示,上月曾發表中資醫藥股下半年前景報告,已預期製藥股份會有調整,但具獨特商業模式的製藥股則可跑贏大市。該行最新報告料中資醫藥股於10月及今年餘下時間將會表現波動,因料利好及利淡因素混集,但相信今年底前可迎來催化劑。

該行表示,重申對中資醫藥股下半年首要買入股份,包括錦欣生殖(01951.HK)及中生製藥(01177.HK),因兩股均為內地製藥及生物製藥的領導企業,而該行看好受惠行業整合及企業創新技術藥企,如中生製藥、恆瑞醫藥(600276.SH)、翰森製藥(03692.HK)、三生製藥(01530.HK)。

花旗估計,大部分中資醫藥股今年第三季業績強勁,料可支持股價表現,但無論如何,藥企面對中央採購的定價及銷售策略改變,公司料將面對壓力,或調整明年指引。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account